Two doses of pandemic influenza A(H1N1) vaccine: tolerability in healthy young children in the Netherlands.
Identifieur interne : 001186 ( Ncbi/Merge ); précédent : 001185; suivant : 001187Two doses of pandemic influenza A(H1N1) vaccine: tolerability in healthy young children in the Netherlands.
Auteurs : Tessa M. Van'T Klooster [Pays-Bas] ; Jeanet M. Kemmeren ; Hester E. De Melker ; Patricia E. Vermeer-De Bondt ; Nicoline A T. Van Der MaasSource :
- Human vaccines [ 1554-8619 ] ; 2011.
Descripteurs français
- KwdFr :
- Effets secondaires indésirables des médicaments (épidémiologie), Enfant d'âge préscolaire, Enquêtes et questionnaires, Femelle, Grippe humaine (), Grippe humaine (immunologie), Humains, Mâle, Nourrisson, Pays-Bas, Rappel de vaccin (), Rappel de vaccin (effets indésirables), Sous-type H1N1 du virus de la grippe A (immunologie), Vaccination (), Vaccination (effets indésirables), Vaccins antigrippaux (administration et posologie), Vaccins antigrippaux (effets indésirables), Vaccins antigrippaux (immunologie).
- MESH :
- administration et posologie : Vaccins antigrippaux.
- effets indésirables : Rappel de vaccin, Vaccination, Vaccins antigrippaux.
- immunologie : Grippe humaine, Sous-type H1N1 du virus de la grippe A, Vaccins antigrippaux.
- épidémiologie : Effets secondaires indésirables des médicaments.
- Enfant d'âge préscolaire, Enquêtes et questionnaires, Femelle, Grippe humaine, Humains, Mâle, Nourrisson, Pays-Bas, Rappel de vaccin, Vaccination.
- Wicri :
- geographic : Pays-Bas.
English descriptors
- KwdEn :
- Child, Preschool, Drug-Related Side Effects and Adverse Reactions (epidemiology), Female, Humans, Immunization, Secondary (adverse effects), Immunization, Secondary (methods), Infant, Influenza A Virus, H1N1 Subtype (immunology), Influenza Vaccines (administration & dosage), Influenza Vaccines (adverse effects), Influenza Vaccines (immunology), Influenza, Human (immunology), Influenza, Human (prevention & control), Male, Netherlands, Surveys and Questionnaires, Vaccination (adverse effects), Vaccination (methods).
- MESH :
- chemical , administration & dosage : Influenza Vaccines.
- geographic : Netherlands.
- adverse effects : Immunization, Secondary, Influenza Vaccines, Vaccination.
- epidemiology : Drug-Related Side Effects and Adverse Reactions.
- immunology : Influenza A Virus, H1N1 Subtype, Influenza Vaccines, Influenza, Human.
- methods : Immunization, Secondary, Vaccination.
- prevention & control : Influenza, Human.
- Child, Preschool, Female, Humans, Infant, Male, Surveys and Questionnaires.
Abstract
During the 2009 influenza pandemic, children aged 6 months up to and including 4 years, without chronic illness, were vaccinated with two doses of Pandemrix(®) through mass vaccination in the Netherlands. During the vaccination campaign a warning was issued about fever after the second dose of Pandemrix(®). Therefore, we investigated the tolerability of both doses Pandemrix(®) in these children. Among parents of children eligible for vaccination, 1500 questionnaires were distributed during both, the first and second mass vaccination session. We asked for the occurrence, time interval, and duration of local reactions and systemic adverse events (AEs). The responses were 36.7% and 29.5% after each dose, respectively. Local reactions were reported in 40.4% and 39.3%, most frequently, pain at the injection site. After the first and second dose, 29.6% and 30.7% of all children experienced fever (mean temperature 38.8{degree sign}C). Other systemic AEs were reported in 41.6% and 42.9% of the children. No differences were seen between the first and second dose for all reported AEs except for pallor. One child was hospitalized after the first dose, but a causal relation to the vaccination was considered improbable. In conclusion, fever was frequently reported in children 6 months up to and including 4 years of age after the first and second dose of Pandemrix(®). However, for almost all AEs, including fever, no dose effect was observed. Reported AEs were mostly mild and all were transient.
DOI: 10.4161/hv.7.10.16692
PubMed: 21957494
Links toward previous steps (curation, corpus...)
- to stream PubMed, to step Corpus: 000E77
- to stream PubMed, to step Curation: 000E77
- to stream PubMed, to step Checkpoint: 000E03
Links to Exploration step
pubmed:21957494Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Two doses of pandemic influenza A(H1N1) vaccine: tolerability in healthy young children in the Netherlands.</title><author><name sortKey="Van T Klooster, Tessa M" sort="Van T Klooster, Tessa M" uniqKey="Van T Klooster T" first="Tessa M" last="Van'T Klooster">Tessa M. Van'T Klooster</name><affiliation wicri:level="1"><nlm:affiliation>Department of Epidemiology and Surveillance, Centre for Infectious Disease Control, National Institute for Public Health and the Environment, Bilthoven, The Netherlands.</nlm:affiliation><country xml:lang="fr">Pays-Bas</country><wicri:regionArea>Department of Epidemiology and Surveillance, Centre for Infectious Disease Control, National Institute for Public Health and the Environment, Bilthoven</wicri:regionArea><wicri:noRegion>Bilthoven</wicri:noRegion></affiliation></author><author><name sortKey="Kemmeren, Jeanet M" sort="Kemmeren, Jeanet M" uniqKey="Kemmeren J" first="Jeanet M" last="Kemmeren">Jeanet M. Kemmeren</name></author><author><name sortKey="De Melker, Hester E" sort="De Melker, Hester E" uniqKey="De Melker H" first="Hester E" last="De Melker">Hester E. De Melker</name></author><author><name sortKey="Vermeer De Bondt, Patricia E" sort="Vermeer De Bondt, Patricia E" uniqKey="Vermeer De Bondt P" first="Patricia E" last="Vermeer-De Bondt">Patricia E. Vermeer-De Bondt</name></author><author><name sortKey="Van Der Maas, Nicoline A T" sort="Van Der Maas, Nicoline A T" uniqKey="Van Der Maas N" first="Nicoline A T" last="Van Der Maas">Nicoline A T. Van Der Maas</name></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="2011">2011</date><idno type="RBID">pubmed:21957494</idno><idno type="pmid">21957494</idno><idno type="doi">10.4161/hv.7.10.16692</idno><idno type="wicri:Area/PubMed/Corpus">000E77</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">000E77</idno><idno type="wicri:Area/PubMed/Curation">000E77</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Curation">000E77</idno><idno type="wicri:Area/PubMed/Checkpoint">000E03</idno><idno type="wicri:explorRef" wicri:stream="Checkpoint" wicri:step="PubMed">000E03</idno><idno type="wicri:Area/Ncbi/Merge">001186</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">Two doses of pandemic influenza A(H1N1) vaccine: tolerability in healthy young children in the Netherlands.</title><author><name sortKey="Van T Klooster, Tessa M" sort="Van T Klooster, Tessa M" uniqKey="Van T Klooster T" first="Tessa M" last="Van'T Klooster">Tessa M. Van'T Klooster</name><affiliation wicri:level="1"><nlm:affiliation>Department of Epidemiology and Surveillance, Centre for Infectious Disease Control, National Institute for Public Health and the Environment, Bilthoven, The Netherlands.</nlm:affiliation><country xml:lang="fr">Pays-Bas</country><wicri:regionArea>Department of Epidemiology and Surveillance, Centre for Infectious Disease Control, National Institute for Public Health and the Environment, Bilthoven</wicri:regionArea><wicri:noRegion>Bilthoven</wicri:noRegion></affiliation></author><author><name sortKey="Kemmeren, Jeanet M" sort="Kemmeren, Jeanet M" uniqKey="Kemmeren J" first="Jeanet M" last="Kemmeren">Jeanet M. Kemmeren</name></author><author><name sortKey="De Melker, Hester E" sort="De Melker, Hester E" uniqKey="De Melker H" first="Hester E" last="De Melker">Hester E. De Melker</name></author><author><name sortKey="Vermeer De Bondt, Patricia E" sort="Vermeer De Bondt, Patricia E" uniqKey="Vermeer De Bondt P" first="Patricia E" last="Vermeer-De Bondt">Patricia E. Vermeer-De Bondt</name></author><author><name sortKey="Van Der Maas, Nicoline A T" sort="Van Der Maas, Nicoline A T" uniqKey="Van Der Maas N" first="Nicoline A T" last="Van Der Maas">Nicoline A T. Van Der Maas</name></author></analytic><series><title level="j">Human vaccines</title><idno type="eISSN">1554-8619</idno><imprint><date when="2011" type="published">2011</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Child, Preschool</term><term>Drug-Related Side Effects and Adverse Reactions (epidemiology)</term><term>Female</term><term>Humans</term><term>Immunization, Secondary (adverse effects)</term><term>Immunization, Secondary (methods)</term><term>Infant</term><term>Influenza A Virus, H1N1 Subtype (immunology)</term><term>Influenza Vaccines (administration & dosage)</term><term>Influenza Vaccines (adverse effects)</term><term>Influenza Vaccines (immunology)</term><term>Influenza, Human (immunology)</term><term>Influenza, Human (prevention & control)</term><term>Male</term><term>Netherlands</term><term>Surveys and Questionnaires</term><term>Vaccination (adverse effects)</term><term>Vaccination (methods)</term></keywords><keywords scheme="KwdFr" xml:lang="fr"><term>Effets secondaires indésirables des médicaments (épidémiologie)</term><term>Enfant d'âge préscolaire</term><term>Enquêtes et questionnaires</term><term>Femelle</term><term>Grippe humaine ()</term><term>Grippe humaine (immunologie)</term><term>Humains</term><term>Mâle</term><term>Nourrisson</term><term>Pays-Bas</term><term>Rappel de vaccin ()</term><term>Rappel de vaccin (effets indésirables)</term><term>Sous-type H1N1 du virus de la grippe A (immunologie)</term><term>Vaccination ()</term><term>Vaccination (effets indésirables)</term><term>Vaccins antigrippaux (administration et posologie)</term><term>Vaccins antigrippaux (effets indésirables)</term><term>Vaccins antigrippaux (immunologie)</term></keywords><keywords scheme="MESH" type="chemical" qualifier="administration & dosage" xml:lang="en"><term>Influenza Vaccines</term></keywords><keywords scheme="MESH" type="geographic" xml:lang="en"><term>Netherlands</term></keywords><keywords scheme="MESH" qualifier="administration et posologie" xml:lang="fr"><term>Vaccins antigrippaux</term></keywords><keywords scheme="MESH" qualifier="adverse effects" xml:lang="en"><term>Immunization, Secondary</term><term>Influenza Vaccines</term><term>Vaccination</term></keywords><keywords scheme="MESH" qualifier="effets indésirables" xml:lang="fr"><term>Rappel de vaccin</term><term>Vaccination</term><term>Vaccins antigrippaux</term></keywords><keywords scheme="MESH" qualifier="epidemiology" xml:lang="en"><term>Drug-Related Side Effects and Adverse Reactions</term></keywords><keywords scheme="MESH" qualifier="immunologie" xml:lang="fr"><term>Grippe humaine</term><term>Sous-type H1N1 du virus de la grippe A</term><term>Vaccins antigrippaux</term></keywords><keywords scheme="MESH" qualifier="immunology" xml:lang="en"><term>Influenza A Virus, H1N1 Subtype</term><term>Influenza Vaccines</term><term>Influenza, Human</term></keywords><keywords scheme="MESH" qualifier="methods" xml:lang="en"><term>Immunization, Secondary</term><term>Vaccination</term></keywords><keywords scheme="MESH" qualifier="prevention & control" xml:lang="en"><term>Influenza, Human</term></keywords><keywords scheme="MESH" qualifier="épidémiologie" xml:lang="fr"><term>Effets secondaires indésirables des médicaments</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Child, Preschool</term><term>Female</term><term>Humans</term><term>Infant</term><term>Male</term><term>Surveys and Questionnaires</term></keywords><keywords scheme="MESH" xml:lang="fr"><term>Enfant d'âge préscolaire</term><term>Enquêtes et questionnaires</term><term>Femelle</term><term>Grippe humaine</term><term>Humains</term><term>Mâle</term><term>Nourrisson</term><term>Pays-Bas</term><term>Rappel de vaccin</term><term>Vaccination</term></keywords><keywords scheme="Wicri" type="geographic" xml:lang="fr"><term>Pays-Bas</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">During the 2009 influenza pandemic, children aged 6 months up to and including 4 years, without chronic illness, were vaccinated with two doses of Pandemrix(®) through mass vaccination in the Netherlands. During the vaccination campaign a warning was issued about fever after the second dose of Pandemrix(®). Therefore, we investigated the tolerability of both doses Pandemrix(®) in these children. Among parents of children eligible for vaccination, 1500 questionnaires were distributed during both, the first and second mass vaccination session. We asked for the occurrence, time interval, and duration of local reactions and systemic adverse events (AEs). The responses were 36.7% and 29.5% after each dose, respectively. Local reactions were reported in 40.4% and 39.3%, most frequently, pain at the injection site. After the first and second dose, 29.6% and 30.7% of all children experienced fever (mean temperature 38.8{degree sign}C). Other systemic AEs were reported in 41.6% and 42.9% of the children. No differences were seen between the first and second dose for all reported AEs except for pallor. One child was hospitalized after the first dose, but a causal relation to the vaccination was considered improbable. In conclusion, fever was frequently reported in children 6 months up to and including 4 years of age after the first and second dose of Pandemrix(®). However, for almost all AEs, including fever, no dose effect was observed. Reported AEs were mostly mild and all were transient.</div></front></TEI><pubmed><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">21957494</PMID><DateCompleted><Year>2012</Year><Month>03</Month><Day>21</Day></DateCompleted><DateRevised><Year>2015</Year><Month>11</Month><Day>19</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1554-8619</ISSN><JournalIssue CitedMedium="Internet"><Volume>7</Volume><Issue>10</Issue><PubDate><Year>2011</Year><Month>Oct</Month></PubDate></JournalIssue><Title>Human vaccines</Title><ISOAbbreviation>Hum Vaccin</ISOAbbreviation></Journal><ArticleTitle>Two doses of pandemic influenza A(H1N1) vaccine: tolerability in healthy young children in the Netherlands.</ArticleTitle><Pagination><MedlinePgn>1048-54</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.4161/hv.7.10.16692</ELocationID><Abstract><AbstractText>During the 2009 influenza pandemic, children aged 6 months up to and including 4 years, without chronic illness, were vaccinated with two doses of Pandemrix(®) through mass vaccination in the Netherlands. During the vaccination campaign a warning was issued about fever after the second dose of Pandemrix(®). Therefore, we investigated the tolerability of both doses Pandemrix(®) in these children. Among parents of children eligible for vaccination, 1500 questionnaires were distributed during both, the first and second mass vaccination session. We asked for the occurrence, time interval, and duration of local reactions and systemic adverse events (AEs). The responses were 36.7% and 29.5% after each dose, respectively. Local reactions were reported in 40.4% and 39.3%, most frequently, pain at the injection site. After the first and second dose, 29.6% and 30.7% of all children experienced fever (mean temperature 38.8{degree sign}C). Other systemic AEs were reported in 41.6% and 42.9% of the children. No differences were seen between the first and second dose for all reported AEs except for pallor. One child was hospitalized after the first dose, but a causal relation to the vaccination was considered improbable. In conclusion, fever was frequently reported in children 6 months up to and including 4 years of age after the first and second dose of Pandemrix(®). However, for almost all AEs, including fever, no dose effect was observed. Reported AEs were mostly mild and all were transient.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>van't Klooster</LastName><ForeName>Tessa M</ForeName><Initials>TM</Initials><AffiliationInfo><Affiliation>Department of Epidemiology and Surveillance, Centre for Infectious Disease Control, National Institute for Public Health and the Environment, Bilthoven, The Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kemmeren</LastName><ForeName>Jeanet M</ForeName><Initials>JM</Initials></Author><Author ValidYN="Y"><LastName>de Melker</LastName><ForeName>Hester E</ForeName><Initials>HE</Initials></Author><Author ValidYN="Y"><LastName>Vermeer-de Bondt</LastName><ForeName>Patricia E</ForeName><Initials>PE</Initials></Author><Author ValidYN="Y"><LastName>van der Maas</LastName><ForeName>Nicoline A T</ForeName><Initials>NA</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2011</Year><Month>10</Month><Day>01</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Hum Vaccin</MedlineTA><NlmUniqueID>101265291</NlmUniqueID><ISSNLinking>1554-8600</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D007252">Influenza Vaccines</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C556153">pandemrix</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D002675" MajorTopicYN="N">Child, Preschool</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D064420" MajorTopicYN="N">Drug-Related Side Effects and Adverse Reactions</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007117" MajorTopicYN="N">Immunization, Secondary</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="Y">adverse effects</QualifierName><QualifierName UI="Q000379" MajorTopicYN="Y">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D007223" MajorTopicYN="N">Infant</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D053118" MajorTopicYN="N">Influenza A Virus, H1N1 Subtype</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D007252" MajorTopicYN="N">Influenza Vaccines</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="N">administration & dosage</QualifierName><QualifierName UI="Q000009" MajorTopicYN="Y">adverse effects</QualifierName><QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D007251" MajorTopicYN="N">Influenza, Human</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName><QualifierName UI="Q000517" MajorTopicYN="Y">prevention & control</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009426" MajorTopicYN="N" Type="Geographic">Netherlands</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011795" MajorTopicYN="N">Surveys and Questionnaires</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D014611" MajorTopicYN="N">Vaccination</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="Y">adverse effects</QualifierName><QualifierName UI="Q000379" MajorTopicYN="Y">methods</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2011</Year><Month>9</Month><Day>30</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2011</Year><Month>10</Month><Day>1</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2012</Year><Month>3</Month><Day>22</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">21957494</ArticleId><ArticleId IdType="pii">16692</ArticleId><ArticleId IdType="doi">10.4161/hv.7.10.16692</ArticleId></ArticleIdList></PubmedData></pubmed><affiliations><list><country><li>Pays-Bas</li></country></list><tree><noCountry><name sortKey="De Melker, Hester E" sort="De Melker, Hester E" uniqKey="De Melker H" first="Hester E" last="De Melker">Hester E. De Melker</name><name sortKey="Kemmeren, Jeanet M" sort="Kemmeren, Jeanet M" uniqKey="Kemmeren J" first="Jeanet M" last="Kemmeren">Jeanet M. Kemmeren</name><name sortKey="Van Der Maas, Nicoline A T" sort="Van Der Maas, Nicoline A T" uniqKey="Van Der Maas N" first="Nicoline A T" last="Van Der Maas">Nicoline A T. Van Der Maas</name><name sortKey="Vermeer De Bondt, Patricia E" sort="Vermeer De Bondt, Patricia E" uniqKey="Vermeer De Bondt P" first="Patricia E" last="Vermeer-De Bondt">Patricia E. Vermeer-De Bondt</name></noCountry><country name="Pays-Bas"><noRegion><name sortKey="Van T Klooster, Tessa M" sort="Van T Klooster, Tessa M" uniqKey="Van T Klooster T" first="Tessa M" last="Van'T Klooster">Tessa M. Van'T Klooster</name></noRegion></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Sante/explor/PandemieGrippaleV1/Data/Ncbi/Merge
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 001186 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Ncbi/Merge/biblio.hfd -nk 001186 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Sante
|area= PandemieGrippaleV1
|flux= Ncbi
|étape= Merge
|type= RBID
|clé= pubmed:21957494
|texte= Two doses of pandemic influenza A(H1N1) vaccine: tolerability in healthy young children in the Netherlands.
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/Ncbi/Merge/RBID.i -Sk "pubmed:21957494" \
| HfdSelect -Kh $EXPLOR_AREA/Data/Ncbi/Merge/biblio.hfd \
| NlmPubMed2Wicri -a PandemieGrippaleV1
| This area was generated with Dilib version V0.6.34. |  |